Multisystemic smooth muscle dysfunction syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:404463OMIM:613834I73.8
Who is this for?
Show terms as
2Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an extremely rare genetic disorder caused by mutations in the ACTA2 gene. This gene provides instructions for making a protein called alpha-smooth muscle actin, which is essential for the proper function of smooth muscle cells throughout the body. Smooth muscles are the muscles you cannot control voluntarily — they line blood vessels, the bladder, the gut, and the airways. Because smooth muscle is found in so many organs, this condition affects multiple body systems. The most serious problems involve the blood vessels, including a characteristic pattern of dilated (widened) and stiff arteries, particularly the aorta. Patients often have a specific brain blood vessel abnormality called Moyamoya disease, which can lead to strokes. Other common features include a fixed, dilated pupil in the eyes (called mydriasis), problems with bladder emptying, reduced gut movement leading to poor digestion, and lung disease. Some patients also have a distinctive pattern of white matter changes in the brain. There is currently no cure for MSMDS. Treatment focuses on managing each affected organ system individually. This may include surgeries to repair blood vessel problems, medications to prevent strokes, and supportive care for bladder and gut issues. Because the disease affects so many systems, patients typically need a team of specialists working together. Early diagnosis is important so that monitoring and preventive measures can be started as soon as possible.

Key symptoms:

Widened or dilated aorta and other large arteriesMoyamoya disease (abnormal blood vessels in the brain)Strokes, including in childhoodFixed, dilated pupils that do not react to lightDifficulty emptying the bladderChronic constipation or poor gut movementLung disease or breathing difficultiesWhite matter abnormalities in the brainPatent ductus arteriosus (a heart defect present at birth)Low blood pressureRecurrent lung infectionsPoor weight gain or failure to thriveDifficulty feeding in infancyCongenital heart defects

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

2 events
May 2024A Retrospective and Prospective Natural History of Genetic Vasculopathies

Massachusetts General Hospital

TrialRECRUITING
Mar 2024Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

The University of Texas Health Science Center, Houston — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Multisystemic smooth muscle dysfunction syndrome.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Phase 11 trial
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Phase 1
Actively Recruiting
PI: Dianna Milewicz, MD, PhD (The University of Texas Health Science Center, Hou) · Sites: Houston, Texas · Age: 199 yrs
Other1 trial
A Retrospective and Prospective Natural History of Genetic Vasculopathies
Actively Recruiting
· Sites: Boston, Massachusetts

No specialists are currently listed for Multisystemic smooth muscle dysfunction syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Multisystemic smooth muscle dysfunction syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Multisystemic smooth muscle dysfunction syndromeForum →

No community posts yet. Be the first to share your experience with Multisystemic smooth muscle dysfunction syndrome.

Start the conversation →

Latest news about Multisystemic smooth muscle dysfunction syndrome

Disease timeline:

New recruiting trial: A Retrospective and Prospective Natural History of Genetic Vasculopathies

A new clinical trial is recruiting patients for Multisystemic smooth muscle dysfunction syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific ACTA2 mutation does my child have, and what does it mean for their prognosis?,How often should brain imaging be done to monitor for Moyamoya disease?,What are the warning signs of a stroke that I should watch for at home?,Is surgical revascularization recommended for my child's brain blood vessel problems?,How should we manage bladder and bowel problems on a daily basis?,Are there any clinical trials or research studies we could participate in?,Should other family members be tested for the ACTA2 mutation?

Common questions about Multisystemic smooth muscle dysfunction syndrome

What is Multisystemic smooth muscle dysfunction syndrome?

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an extremely rare genetic disorder caused by mutations in the ACTA2 gene. This gene provides instructions for making a protein called alpha-smooth muscle actin, which is essential for the proper function of smooth muscle cells throughout the body. Smooth muscles are the muscles you cannot control voluntarily — they line blood vessels, the bladder, the gut, and the airways. Because smooth muscle is found in so many organs, this condition affects multiple body systems. The most serious problems involve the blood vessels, including a ch

How is Multisystemic smooth muscle dysfunction syndrome inherited?

Multisystemic smooth muscle dysfunction syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Multisystemic smooth muscle dysfunction syndrome typically begin?

Typical onset of Multisystemic smooth muscle dysfunction syndrome is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Multisystemic smooth muscle dysfunction syndrome?

Yes — 2 recruiting clinical trials are currently listed for Multisystemic smooth muscle dysfunction syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.